Introduction {#Sec1}
============

Cetirizine (CTZ, Fig. [1](#Fig1){ref-type="fig"}a); is non-sedating antihistamine with long acting activity for treatment of urticarial and rhinitis \[[@CR1]\]. It is (\[2-\[4-\[(4-chlorophenyl) phenylmethyl\]-1-piperazinyl\] ethoxy\] acetic acid). The BP suggested a potentiometric titration method for determination of CTZ in its pure form; while it recommended an HPLC method for both cetirizine oral solution and tablets \[[@CR2]\]. Different analytical procedures were reported for its determination including HPLC \[[@CR3]--[@CR6]\], HPTLC \[[@CR7]\], capillary electrophoresis \[[@CR8]\] and spectrophotometry \[[@CR9]\].Fig. 1The structural formulae of the studied drugs. **a** Cetirizine, **b** phenylpropanolamine, **c** nimesulide

Phenylpropanolamine hydrochloride (PPA, Fig. [1](#Fig1){ref-type="fig"}b) is a nasal decongestant mainly used in combinations for relief of cold symptoms as it has indirect sympathomimetic activity \[[@CR1]\]. Its chemical name is (1RS, 2SR)-2-amino-1-phenylpropan-1-ol. The BP described non aqueous potentiometric titration for PPA \[[@CR2]\]. The USP suggested non-aqueous titration method using glacial acetic acid for PPA pure form and HPLC method for its capsules, extended released capsules, tablets, extended released tablets and oral solutions \[[@CR10]\]. There are different methods used for PPA determination as HPLC \[[@CR5], [@CR6], [@CR11]\], capillary gas chromatography \[[@CR12]\], spectrophotometry \[[@CR13]\] and flow injection \[[@CR14]\] methods.

Nimesulide (NMS, Fig. [1](#Fig1){ref-type="fig"}c) is a non-steroidal anti-inflammatory that acts by inhibition of COX-2 enzyme \[[@CR1]\]. It is 4′-nitro-2′-phenoxymethanesulphonanilide. The BP mentioned potentiometric titration method for NMS \[[@CR2]\]. The literature revealed several methods for NMS determination as HPLC \[[@CR15]--[@CR17]\], spectrophotometry \[[@CR18]\] and TLC \[[@CR19]\] methods.

The pharmaceutical preparation that contains the three drugs in a tablet dosage form is consisting of (5 mg CTZ, 25 mg PPA and 100 mg NMS) \[[@CR20]\]. The current study deals with two simple and sensitive methods for the simultaneous estimation of the three analytes included in this tablet preparation. The spectrophotometric method is a simple and sensitive cost-effective method. It doesn't need any reagents or other tedious procedures. Although the literature contains two methods for the simultaneous determination of both CTZ and PPA \[[@CR5], [@CR6]\]; our proposed HPLC method is superior to the both mentioned methods. Despite Sunil et al. \[[@CR5]\] provides an HPLC method for application in plasma and urine, it is less sensitive than our proposed method. Suryan et al. method \[[@CR6]\] seeks from the disadvantage of longer retention times, and broader peaks. Our proposed HPLC method, consequently is more sensitive, rapid with sharper peaks than the other mentioned methods owing to the use of monolithic column through this study.

Experimental {#Sec2}
============

Apparatus {#Sec3}
---------

A Shimadzu (Kyoto, Japan) UV-1601 PC, UV--visible double-beam spectrophotometer was used. The third derivative spectra of the drugs were derived in the wavelength range (200--400) nm using Δλ = 8 nm and scaling factor = 10.

A Shimadzu LC-20 AD prominence liquid chromatograph (Japan) was used for HPLC analysis; with a Rheodyne injector valve and a SPD-20A UV detector set at wave length 215 nm.

Materials and reagents {#Sec4}
----------------------

Cetirizine hydrochloride pure sample was obtained from Apex Co., Cairo, Egypt (Batch No \# 3003CZ8RJ) with 99.95% purity. Phenylpropanolmine hydrochloride (99.88% purity) was kindly brought from Cid Co., Egypt with Batch No \# 41204. Nimesulide base was used with purity 99.90% as mentioned by the manufacturer, Batch No \# 0006044. It is provided from Pharaonia Co., Alex, Egypt.

Organic solvents (HPLC grade) were purchased from Sigma-Aldrich (Germany).

Sodium hydroxide and sodium dihydrogen phosphate were purchased from ADWIC Co. (Egypt). Orthophosphoric acid (85%, w/v) was provided from Riedel-deHäen (Germany).

Chromatographic conditions {#Sec5}
--------------------------

Chromolith^®^ performance (RP-18 monolithic, 100 mm × 4.6 mm i.d.) is the column used for the investigation. The mobile phase used is a mixture of methanol and buffer (0.1 M phosphate buffer) in a ratio of (60:40 v/v) respectively. The pH was adjusted to be 7. The flow rate was 1 mL/min and the wavelength was 215 nm.

Standard solutions {#Sec6}
------------------

CTZ, PPA and NMS 400 µg/mL stock solutions were prepared by dissolving 40 mg of each the studied drugs in 100 mL methanol and further dilution was carried out to achieve the required concentrations for each of the two methods.

General procedures {#Sec7}
------------------

### Construction of calibration graph {#Sec8}

#### Spectrophotometric method {#Sec9}

Serial dilutions of stock solutions were prepared to give concentrations of 8--90, 20--100 and 20--200 µg/mL for CET, PPA and NMS respectively. The third order derivative amplitudes were measured at 238, 218 and 305 nm for CTZ, PPA and NMS. A plot of the third derivative amplitude against the concentration was constructed to give the calibration curves.

#### Chromatographic method {#Sec10}

CTZ, PPA and NMS working standard solutions were prepared by serial dilution of the stock solution in a 10 mL flask to obtain final concentration ranges; 5--40 µg/mL for CTZ, 10--100 µg/mL for PPA, and 10--120 µg/mL for NMS. The solutions were completed to the required volume by the mobile phase and were subjected to the chromatographic analysis under optimum conditions. Calibration graphs were constructed by plotting area under the curve against drug concentration in μg/mL \[[@CR6]--[@CR8]\].

### Analysis of CTZ, PPA and NMS laboratory-prepared mixtures {#Sec11}

Mixtures of CTZ, PPA and NMS in the ratio of 1:5:20 were prepared within the concentration ranges and analysed by the spectrophotometric strategy or the chromatographic strategy under the optimum conditions described in "[Chromatographic conditions](#Sec5){ref-type="sec"}". The percent recoveries were determined using regression equations or calibration graphs.

### Analysis of CTZ, PPA and NMS in their co-formulated tablet {#Sec12}

Laboratory co-formulated tablets were prepared as follows; accurately weighed 5 mg CTZ, 25 mg PPA and 100 mg NMS are mixed with 15 mg lactose, 10 mg magnesium stearate, 15 mg maize starch and 20 mg talc. One tablet was weighed, transferred to 100 mL volumetric flask, and completed to the mark with methanol. The solution undergoes 30 min sonication and then filtration till clear solution was obtained clear solution. Aliquots were taken within the concentration ranges for each drug (Table [1](#Tab1){ref-type="table"}), and the chromatographic or spectrophotometric procedure was followed for calculating the percent recoveries \[[@CR18]\].Table 1Analytical performance data for the determination of the studied drugs by the proposed methodsParameter3rd Derivative methodHPLC methodCTZPPANMSCTZPPANMSLinearity range (µg/mL)8--9020--10020--2005--4010--10010--120Intercept (a)0.006−0.028−0.0361.3 × 10^4^4.926 × 10^5^−7.217 × 10^4^Slope (b)0.0010.0020.0024.2399 × 10^4^3.1 × 10^4^9.343 × 10^4^Correlation coefficient (r)0.99990.99990.99990.99990.99980.9999S.D. of residuals (S~y/x~)5.061 × 10^−4^1.146 × 10^−3^1.169 × 10^−3^5.015 × 10^3^1.912 × 10^4^6.67 × 10^4^S.D. of intercept (S~a~)3.371 × 10^−4^1.16 × 10^−3^1.143 × 10^−3^3.21 × 10^3^1.377 × 10^4^4.908 × 10^4^S.D. of slope (S~b~)6.828 × 10^−6^1.794 × 10^−5^9.583 × 10^−6^1.667 × 10^2^2.723 × 10^2^7.00 × 10^2^S.D.0.941.511.280.441.491.10% RSD^a^0.951.531.290.441.491.10% Error^b^0.390.860.530.180.610.45LOD (µg/mL)^c^1.101.901.900.251.471.70LOQ (µg/mL)^d^3.405.805.500.764.405.25^a^Percentage relative standard deviation^b^Percentage relative error^c^Limit of detection^d^Limit of quantitation

Results {#Sec13}
=======

Third derivative spectrophotometric method {#Sec14}
------------------------------------------

The simultaneous analysis of the three drugs by classical spectrophotometric method is a challenge owing to the strong overlapping of their zero order spectra (Fig. [2](#Fig2){ref-type="fig"}), and the difference between their concentrations in the tablet. Also there was strong overlapping in first and second order derivative spectra, third derivative spectrophotometry was used in the analysis of the three drugs mixture without interference from each other (Fig. [3](#Fig3){ref-type="fig"}). CTZ could be assayed by measuring its third derivative amplitude at zero crossing points of NMS and PPA at 238 nm (Fig. [4](#Fig4){ref-type="fig"}) and PPA could be determined at zero crossing points of CTZ and NMS at 218 nm (Fig. [5](#Fig5){ref-type="fig"}). Also NMS was determined at zero crossing points of CTZ and PPA at 305 nm (Fig. [6](#Fig6){ref-type="fig"}).Fig. 2Absorption spectra of: (a) CTZ (b) PPA (c) NMS, conc. of each 20 µg/mL in methanol Fig. 3Third order derivative absorption spectra of: (a) CTZ (8 µg/mL), (b) PPA (40 µg/mL), (c) NMS (160 µg/mL) in methanol Fig. 4Third order derivative absorption spectra of: (a--g) CTZ (8, 10, 16, 20, 50, 60 and 90 µg/mL), (h) NMS (20 µg/mL), (i) PPA (20 µg/mL) Fig. 5Third order derivative absorption spectra of: (a--e) PPA (20, 40, 50, 80 and 100 µg/mL), (f) CTZ (20 µg/mL), (g) NMS (20 µg/mL) Fig. 6Third order derivative absorption spectra of: (a--e) NMS (20, 30, 40, 50 and 80 µg/mL), (f) CTZ (20 µg/mL), (g) PPA (20 µg/mL)

Chromatographic method (HPLC) {#Sec15}
-----------------------------

### Optimization of the chromatographic performance {#Sec16}

Studying of chromatographic conditions was carried out to reach the optimum conditions that achieve good and efficient separation. Figure [7](#Fig7){ref-type="fig"} shows typical chromatogram for CTZ, PPA and NMS laboratory-prepared mixture and Fig. [8](#Fig8){ref-type="fig"} shows the typical chromatogram for laboratory prepared tablet.Fig. 7Typical chromatogram of laboratory prepared mixture under the described chromatographic conditions: (a) PPA (30 µg/mL), (b) NMS (120 µg/mL), (c) CTZ (6 µg/mL) (s) solvent front Fig. 8Typical chromatogram of laboratory prepared co-formulated tablet under the described chromatographic conditions: (a) PPA (30 µg/mL), (b) NMS (120 µg/mL), (c) CTZ (6 µg/mL) (s) solvent front

#### Column choice {#Sec17}

Reversed-phase Chromolith^®^ performance (RP-18 monolithic, 100 mm × 4.6 mm i.d.) and Promosil ODS 100 A column (250 × 4.6 mm i.d. 5 µm particle size) were tried during the separation. The first column was the suitable one as it resulted in well resolved peaks in shorter time.

#### Appropriate wavelength choice {#Sec18}

The UV absorption spectra of the studied drugs in methanol show maxima at 211 and 231 nm for CTZ, 218 nm for PPA and 238, 296 and 307 nm for NMS (Fig. [2](#Fig2){ref-type="fig"}). HPLC chromatograms for studied drugs were scanned from 200 to 400 nm to determine the suitable wavelength and it was found that 215 nm was the suitable wavelength as the studied drugs showed high absorbance at this wavelength especially CTZ as it found in low concentration in the tablet dosage form.

#### Mobile phase composition {#Sec19}

Different modifications were done for the mobile phase to enhance the efficiency of the separation procedures as illustrated in Table [2](#Tab2){ref-type="table"}.Table 2Optimization of the chromatographic conditions for separation of a mixture of cetirizine, phenylpropanolamine and nimesulide by the proposed HPLC methodParameterNo. of theoretical plates (N)Resolution (Rs)Tailing factor (T)Capacity factor (K')Selectivity factor (α)CTZPPANMSCTZ/NMSNMS/PPACTZPPANMSCTZPPANMSCTZ/NMSNMS/PPAPH of the mobile phase 3133097919471.23.81.261.391.252.10.331.51.44.5 4.61398124615481.254.61.311.51.372.610.3672.041.285.6 62351124814902.14.681.301.351.303.470.742.561.363.45 *72432179428043.85.11.191.111.234.51.052.81.642.6*Conc. of phosphate buffer 0.051947169624971.14.11. 341.491.383.41.062.751.242.5 *0.12432179428043.85.11. 191.111.234.51.052.81.642.6* 0.21146128018551.93.661.231.521.363.40.582.051.73.55Conc. of methanol (% v/v) 50%1513130921332.14.12.070.991.324.781.13.41.43.3 *60%2432179428043.85.11.191.111.234.51.052.81.642.6* 70%2396127114960.53.82.221.91.322.471.022.31.072.25 80%1638122913690.742.11.231.091.331.860.991.621.151.64Type of organic modifier *Methanol2432179428043.85.11.191.111.234.51.052.81.642.6* Acetonitrile2278137417952.14.11.360.771.273.20.52.031.594.6 n-Propanol192090010582.43.93.221.92.32.880.421.881.54.5Flow rate (mL/min) 0.81889112325432.43.91.21.561.283.40.981.81.881.84 *1.02432179428043.85.11.191.111.234.51.052.81.642.6* 1.22117124721781.12.91.321.561.352.91.002.31.32.30Italic values indicate the optimum chromatographic conditionsNumber of theoretical plates (N) = $\documentclass[12pt]{minimal}
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Type of organic modifier

Upon studying different organic solvents; it was found that acetonitrile and n-propanol showed overlapping between solvent peak and PPA giving split peak. Methanol was selected for optimum chromatographic conditions, as it gave higher number of theoretical plates with well resolved sharp peaks.

Ratio of organic modifier

The mobile phase which gives rapid separation of CTZ, PPA and NMS in good resolution is methanol: 0.1 M phosphate buffer in the ratio (60: 40, v/v). As the ratio of methanol increased the retention time of CTZ, PPA and NMS was decreased. The ratios 70 and 80% v/v of methanol caused overlapping between CTZ and NMS. CTZ band broadening was observed with ratio 50% (Table [2](#Tab2){ref-type="table"}).

Ionic strength of phosphate buffer

0.1 M phosphate buffer was used as it gaves the highest number of theoretical plates with good resolution. Decreasing or increasing the ionic strength of phosphate buffer results in lower resolution or overlapping peaks.

Validation of the method {#Sec20}
------------------------

### Data analysis {#Sec21}

A linear relationship was established by plotting either the peak area or the derivative amplitude against the drug concentration in µg/mL for the HPLC and the spectrophotometric method respectively. The ranges of linearity were shown in Table [1](#Tab1){ref-type="table"}. Equations referred to linear regression analysis are explained here:

Third derivative spectrophotometric method:
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HPLC method:
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Theoretical basis assumes that the standard curve may be close to the origin, but practically it is rather difficult due to the presence of a reading for the solvent or the blank reading. As the intercept decreases in the calculations, this reflects that the solvent reading is almost near to zero \[[@CR21]\]. Linearity of the calibration curves was proved through statistical analysis \[[@CR21]\] of the data (Table [1](#Tab1){ref-type="table"}).

The limit of quantitation and limit of detection were calculated according to ICH recommendations \[[@CR22]\].
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In terms of accuracy; the results generated from the proposed methods were compared with those of well-established previous reports methods. The comparison method for CTZ and PPA describes reversed phase HPLC method \[[@CR6]\] for simultaneous determination of both drugs using C~18~ column with UV detection at 217 nm. Concerning comparison method for determination of NMS; HPLC method \[[@CR15]\] was utilized acetonitrile: 0.05M KH~2~PO~4~. The detection was carried out at 230 nm on C~18~ column. Accuracy was assessed through comparing the results of the proposed and the comparison methods and there was non-significant difference between the performance of them (Table [3](#Tab3){ref-type="table"}). The ratio of CTZ, PPA and NMS in the tablet is not covered in the comparison method.Table 3Assay results for the determination of the studied drugs in pure form by the proposed and comparison methodsCompound3rd derivative methodHPLC methodComparison methods \[[@CR6], [@CR15]\]Amount taken (μg/mL)Amount found (μg/mL)% FoundAmount taken (μg/mL)Amount found (μg/mL)% FoundAmount taken (μg/mL)Amount found (μg/mL)% FoundCTZ8.007.998.755.004.90598.105.004.9899.5810.0010.00100.006.005.91898.637.007.04100.5916.0016.999.388.008.036100.459.008.9899.7750.0049.098.0010.0010.051100.5160.0059.999.8320.0020.172100.8690.0088.0097.7840.0039.91899.80Mean98.9699.7399.98± S.D.0.940.440.58*t*1.720.365*F*3.044.36PPA20.0020.00100.010.009.84298.4210.009.89898.9830.0029.5798.5825.0024.93299.7311.0011.204101.8540.0039.598.7530.0030.334101.1112.0011.89899.1550.0048.597.0035.0034.26397.8980.0078.598.1350.0050.877101.75100.0099.099.0100.099.899.75Mean98.5899.7899.99± S.D.1.231.491.61*t*1.660.203*F*2.601.17NMS20.0020.0100.010.0010.10101.0750.0050.71101.4230.0029.5098.3330.0030.257100.8670.0068.8298.3140.0039.0097.5040.0040.254100.64100.00100.47100.47100.00100.5100.550.0049.48298.96180.00179.5099.72100.0099.04899.05200.00198.0099.00120.00120.85100.71Mean99.18100.22100.07± S.D.1.281.11.53*t*0.9890.179*F*2.022.8Each result is the average of three separate determinationsThe value of tabulated *t* and *F* are 2.20 and 19.29, respectively at P = 0.05 \[[@CR21]\]

Repeatability and intermediate precision were tested to verify the precision of the proposed methods and the results were summarized in Table [4](#Tab4){ref-type="table"}.Table 4Precision data for the determination of the studied drugs by the proposed methodsParametersIntra-dayInter-day$\documentclass[12pt]{minimal}
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                \begin{document}$$\overline{\text{x}} \pm {\text{S}} . {\text{D}}$$\end{document}$% RSD% Error3rd Derivative method CTZ (μg/mL)  899.04 ± 1.041.050.61100.05 ± 0.240.240.14  2098.04 ± 0.450.460.2798.8 ± 0.270.270.16  4097.65 ± 0.530.540.3198.93 ± 0.250.250.15 PPA (μg/mL)  2098.89 ± 1.271.290.7499.08 ± 0.850.860.49  50100.7 ± 1.851.841.0699.99 ± 1.421.420.82  10099.2 ± 1.831.851.07100.59 ± 1.181.170.68 NMS (μg/mL)  4098.23 ± 0.770.790.4599.27 ± 1.091.10.63  10099.27 ± 1.221.320.71100.6 ± 0.60.600.34  12098.32 ± 0.620.630.3699.91 ± 1.021.020.59HPLC method CTZ (μg/mL)  898.63 ± 0.950.960.56100.53 ± 0.680.670.39  2098.87 ± 0.490.500.29100.75 ± 0.40.390.23  4098.18 ± 0.470.480.2798.15 ± 1.11.120.65 PPA (μg/mL)  2098.23 ± 0.550.560.3299.53 ± 0.490.50.29  5098.07 ± 0.150.160.0999.88 ± 0.170.170.10  10098.23 ± 0.830.830.4998.94 ± 0.210.220.12 NMS (μg/mL)  4098.52 ± 0.620.630.3698.77 ± 0.420.420.24  10098.67 ± 0.360.360.2199.45 ± 0.520.520.30  12098.52 ± 0.950.960.55100.24 ± 0.870.870.5Each result is the average of three separate determinations

### Robustness (for the HPLC method) {#Sec22}

Some variables were changed on constancy of others for robustness investigation. These variables included; pH (6.9 ± 0.1) and phosphate buffer concentration (0.1 ± 0.005 M). These small changes had no effect on the separation and resolution of CTZ, PPA and NMS. This gave a good indication for the reliability of the proposed method.

Application in pharmaceutical preparations {#Sec23}
------------------------------------------

### Analysis of laboratory prepared mixtures {#Sec24}

A successful determination for the three drugs in their laboratory prepared mixtures was performed and summarized in Table [5](#Tab5){ref-type="table"}.Table 5Assay results for the determination of the studied drugs in different synthetic mixtures in different pharmaceutical ratiosParameterAmount taken (μg/mL)Proposed methodComparison methods \[[@CR6], [@CR15]\]Amount found (μg/mL)% FoundAmount taken (μg/mL)% FoundCTZPPANMSCTZPPANMSCTZPPANMSCTZPPANMSCTZPPANMS3rd Derivative method8.040.0160.07.840.0157.097.5100.098.135.0010.015.099.1899.77101.39.045.0180.08.845.0180.598.89100.0100.35.5011.016.5100.3100.9100.510.050.0200.09.749.0199.098.098.0099.506.0012.018.0101.899.4398.9912.024.036.012.223.540.0101.797.92100.08.008.008.0098.0999.8199.4940.040.040.039.140.040.0100.0100.0100.010.010.010.0100.799.7799.63Mean99.2198.1899.59100.099.9499.98± S.D.1.671.180.951.540.800.34*t*1.220.1390.70*F*1.391.161.12HPLC method5.025.0100.04.8939.9598.4497.70100.298.445.0010.015.099.1899.77101.35.527.5110.05.5744.11110.2101.3100.6100.25.5011.016.5100.3100.9100.56.030.0120.06.0250.60121.05100.499.45100.96.0012.018.0101.899.4398.9912.024.036.0012.023.736.64100.399.64101.88.008.008.0098.0999.8199.4940.040.040.0039.939.539.6999.9899.9899.2510.010.010.0100.799.7799.63Mean99.9199.97100.1100.099.9499.98± S.D.0.550.531.061.570.800.34*t*0.140.1220.24*F*1.161.512.1Each result is the average of three separate determinationsThe value of tabulated *t* and *F* are 2.13 and 6.4 respectively at P = 0.05

### Dosage form analysis {#Sec25}

Co-formulated tablets was also analyzed using the proposed HPLC and spectrophotometric methods as illustrated in Table [6](#Tab6){ref-type="table"}. The results of statistical analysis were satisfactory as indicated by Student's *t* test and variance ratio *F* test \[[@CR21]\].Table 6Assay results for the determination of the studied drugs in their laboratory prepared co-formulated tabletsParameterAmount taken (μg/mL)Proposed methodComparison methods \[[@CR6], [@CR15]\]Amount found (μg/mL)% FoundAmount taken (μg/mL)%FoundCTZPPANMSCTZPPANMSCTZPPANMSCTZPPANMSCTZPPANMS3rd Derivative method8.040.0160.07.940.0161.598.75100.098.135.010.090.099.7299.2998.089.045.0180.09.0145.5183.0100.1101.199.446.011.095.0100.5101.397.2610.050.0200.09.950.1202.099.00100.298.27.012.0100.099.8099.4199.5Mean99.29100.498.6100.099.9998.28± S.D.0.720.140.740.461.120.46*t*1.481.170.397*F*2.851.052.36HPLC method5.025.0100.04.9725.10101.0599.32100.4101.15.010.090.099.7299.2998.085.527.5110.05.5727.3121.05101.299.3100.96.011.095.0100.5101.397.266.030.0120.05.9730.1107.999.43100.298.097.012.0100.099.899.4199.5Mean99.9899.97100.0100.099.9998.28± S.D.1.270.611.660.461.120.46*t*0.0350.0451.49*F*6.0463.72.205Each result is the average of three separate determinationsThe value of tabulated *t* and *F* are 2.92 and 19.00 respectively at P = 0.05 \[[@CR21]\]

Discussion {#Sec26}
==========

Third derivative spectrophotometry was used to analyze CTZ, PPA and NMS without interference from each other (Fig. [3](#Fig3){ref-type="fig"}). This method is simple, sensitive and efficient alternative to spectrophotometric methods mentioned for each of the three drugs in the literature \[[@CR9], [@CR13], [@CR18]\], as it doesn't need any reagents or additional time consuming steps.

The proposed approach also describes a novel HPLC method for the simultaneous determination of CTZ, PPA and NMS on a monolithic column. The established method is capable to separate the drugs with high efficacy and high resolution factor and within a short analysis time.

Conclusion {#Sec27}
==========

The current work provides the first method for the simultaneous analysis of CTZ, PPA and NMS in their pharmaceutical formulations. The developed spectrophotometric method is simple, rapid and economic. The HPLC method is a sensitive, reliable and time-saving method where separation of the studied analytes is achieved in less than 8 min. Moreover, the proposed methods overcome the analytical problems raised by the ratio of CTZ, PPA relative to NMS (1:5:20) and therefore could be used in the analysis of their co-formulated tablets in quality control laboratories.

CET

:   cetirizine

PPA

:   phenylpropanolamine

NMS

:   nimesulide

ICH

:   international conference on harmonization

LOQ

:   limit of quantification

LOD

:   limit of detection
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